Abstract

ABSTRACTUp to 41% of hepatocellular carcinomas (HCCs) result from activating mutations in the CTNNB1 gene encoding β-catenin. HCC-associated CTNNB1 mutations stabilize the β-catenin protein, leading to nuclear and/or cytoplasmic localization of β-catenin and downstream activation of Wnt target genes. In patient HCC samples, β-catenin nuclear and cytoplasmic localization are typically patchy, even among HCC with highly active CTNNB1 mutations. The functional and clinical relevance of this heterogeneity in β-catenin activation are not well understood. To define mechanisms of β-catenin-driven HCC initiation, we generated a Cre-lox system that enabled switching on activated β-catenin in (1) a small number of hepatocytes in early development; or (2) the majority of hepatocytes in later development or adulthood. We discovered that switching on activated β-catenin in a subset of larval hepatocytes was sufficient to drive HCC initiation. To determine the role of Wnt/β-catenin signaling heterogeneity later in hepatocarcinogenesis, we performed RNA-seq analysis of zebrafish β-catenin-driven HCC. At the single-cell level, 2.9% to 15.2% of hepatocytes from zebrafish β-catenin-driven HCC expressed two or more of the Wnt target genes axin2, mtor, glula, myca and wif1, indicating focal activation of Wnt signaling in established tumors. Thus, heterogeneous β-catenin activation drives HCC initiation and persists throughout hepatocarcinogenesis.

Highlights

  • Liver cancer is the seventh most commonly occurring cancer in the world and the third highest contributor to cancer-related mortality (Ghouri et al, 2017)

  • This transgenic line consists of CreERT2 cDNA, encoding Cre recombinase fused to the modified ligand-binding domain of the human estrogen receptor (ERT2) (Branda and Dymecki, 2004; Feil et al, 1997; Metzger and Chambon, 2001), downstream of the hepatocyte-specific fabp10a promoter (Her et al, 2003b)

  • The lox-switch part of our modular system consists of the Tg(fabp10a:loxP-BFP-loxP-Xla.Ctnnb1) line, hereafter referred to as Tg(fabp10a:flox-pt-β-cat), wherein the fabp10a promoter drives expression of activated β-catenin preceded by a blue fluorescent protein (BFP)-STOP cassette flanked by loxP sites (Fig. 1A)

Read more

Summary

Introduction

Liver cancer is the seventh most commonly occurring cancer in the world and the third highest contributor to cancer-related mortality (Ghouri et al, 2017). Hepatocellular carcinoma (HCC) comprises over 90% of all primary liver cancers (Lin et al, 2017). Approved chemotherapeutic strategies against HCC include multi-kinase inhibitors and immune-checkpoint inhibitors. Patient response to these drugs and improvement in survival are marginal (Zhu and Hoshida, 2018). Genome-wide analyses of clinical HCC samples reveal a range of functional molecular aberrations that can. Received 10 September 2019; Accepted 24 September 2019 be grouped into distinct molecular subclasses (Chiang et al, 2008). A substantial subset of HCC (13–41%) is defined by activating mutations in the gene encoding β-catenin (CTNNB1) (Khalaf et al, 2018)

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call